Mitochondrial permeability transition pore (mPTP)-opening inhibitor, novel compound exhibiting mPTP-opening inhibitory activity, and use therefor

A method for preventing or treating a disease, symptom or disorder caused by opening of mitochondrial permeability transition pore (mPTP), comprising administering an effective amount of a compound represented by formula (I):

• wherein
• R1 represents a hydrogen, a halogen, or a substituted or unsubstituted amino,
• R2, R3, R4 and R5 satisfy either one of the following conditions (i) and (ii):
• (i)
• R2 represents a hydrogen or a substituted or unsubstituted C1 to C5 alkyl,
• R3 and R4 together form a —O—C(═O)—, wherein a carbon atom to which R3 is attached is bound to an O, and a carbon atom to which R4 is attached is bound to a C(═O), and
• R5 represents a hydrogen,
• (ii)
• R2 represents a hydrogen or a substituted or unsubstituted C1 to C5 alkyl, and
• R3, R4 and R5 each represent a hydrogen,
• R6 represents a hydrogen or a hydroxyl, and
• R7, R8, R9 and R10 satisfy either one of the following conditions (xi) and (xii)
• (xi)
• R7 and R8 together form an oxo (═O), and
• R9 and R10 together form an oxo (═O),
• (xii)
• R7 and R9 each represent a hydroxyl,
• R8, together with a carbon atom attached thereto and an adjacent carbon atom, forms an ethene-1,2-diyl, and
• R10, together with a carbon atom attached thereto and an adjacent carbon atom, forms an ethene-1,2-diyl,
• a bond represented by a solid line and a dotted line is a single bond or a double bond,
• R11 represents a —C(═O)—NH2 or a —CN,
• a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, to a subject in need of the prevention or treatment of the disease, symptom or disorder,
• wherein the disease, symptom or disorder caused by opening of mitochondrial permeability transition pore (mPTP) is at least one selected from the group consisting of ischemia-reperfusion injury in percutaneous coronary angioplasty, and a neurodegenerative disease.